← ANALYST RATINGS · TIPRANKS
Immuneering (IMRX): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $14.00, the highest $18.00, the lowest $12.00. The average is +290.0% from the last price of $3.59.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | −2.5% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | −2.5% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Hold | −2.5% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | −2.5% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | −2.5% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Hold | −2.5% | Reiterated | 13.10.26on TipRanks 07:05 | — | |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $12.00 | Buy | +234.3% | Reiterated | 02.10.26on TipRanks 09:10 | +0.3%next day −1.4% · 5 days −4.4% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $14.00 | Buy | +290.0% | Reiterated | 25.09.26on TipRanks Sep 28 06:35 | −2.2%next day −1.8% · 5 days −4.5% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $12.00 | Buy | +234.3% | Reiterated | 17.08.26on TipRanks 07:38 | +3.6%next day −3.0% · 5 days +0.4% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $11.00 → $18.00+63.6% | Buy | +401.4% | Reiterated | 05.08.26on TipRanks 16:15 | +1.8%next day +0.5% · 5 days +15.4% | ↗ |
| Li Watsek★★★★★★★★★★#11877 · hits 39% · avg −9.1% | Cantor Fitzgerald | $17.00 | Buy | +373.5% | Initiated | 08.07.26on TipRanks 07:00 | +8.7%next day −3.9% · 5 days −8.0% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $20.00 | Buy | +457.1% | Reiterated | 19.05.26on TipRanks 16:30 | +1.6%next day +3.8% · 5 days −1.0% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $30.00 | Buy | +735.7% | Reiterated | 09.03.26on TipRanks Mar 10 03:50 | +4.6%next day +0.2% · 5 days −10.4% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $15.00 | Buy | +317.8% | Initiated | 31.10.25on TipRanks 09:30 | +6.8%next day −4.7% · 5 days +1.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Immuneering
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $14.60 at a price of $4.09 (+256.5%); now: $14.00 at $3.59 (+290.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 13 | 9 | 9 | 8 | 8 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.31 (from $-0.37 to $-0.27). Last quarter: $-0.27.
Best top-analyst consensus in the sector · Healthcare
About Immuneering
- CEO: Benjamin J. Zeskind
- Employees: 57
- 245 Main Street, Cambridge, MA, 02142, US
- immuneering.com
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Data from the stock’s TipRanks forecast page, read 112 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗